UNSPSC 51401552: Talampanel

This classification denotes a cns stimulant with the molecular formula C19H19N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CVS43XG1L5, chemically known as 7h-1,3-dioxolo(4,5-h)(2,3)benzodiazepine, 8,9-dihydro-7-acetyl-5-(4-aminophenyl)-8-methyl-, (r)- but generally known as talampanel, which bears US NIH Compound Identifier 164509. The term TALAMPANEL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42).

Most nations schedule talampanel under HS 29349990 and SITC 51579. As of Q4 2014, TALAMPANEL remains the US FDA Preferred Term for this commodity. Talampanel bears US NLM identifiers UMLS ID C0250723 and NCI Concept Code C38139. SMILES: CC1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3.

UNSPSC 51401552 Talampanel, a Commodity code, shows limited recent state and local procurement activity aligned with its nominal pharmaceutical product scope. The three recent opportunities tagged under this code involve naloxone and safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—a divergent set that suggests the code may be capturing pharmaceutical-adjacent procurements broadly rather than talampanel specifically. State and local governments buying under this code path are purchasing pharmaceutical products and pharmacy benefit program services through a mix of county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Recent activity includes Seminole County, Florida's IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a community health building; the Texas Health and Human Services Commission's RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with pricing evaluations weighted heavily (75 percent) on price competitiveness and effective contract dates of July 1, 2026. Activity spans Florida, Texas, and Minnesota with participation from other states through cooperative arrangements. The code shows no recent activity suggesting concentration in a particular state or issuing-body type.